Affiliation:
1. From the Department of Neurology, Far Eastern Memorial Hospital
Abstract
Vaccine-induced immune thrombotic thrombocytopenia (VITT), also known as thrombosis with thrombocytopenia syndrome, is a rare complication of ChAdOx1 nCoV-19 (AZD1222) vaccine administration. The overall incidence of VITT worldwide is one case per 100 000 exposures. Because of the high mortality rate from VITT, thorough monitoring is crucial to predict the risk of occurrence. The underlying risk factors for VITT are not fully understood. Potential risk factors include sex (female) and young age (<50 years), but further research must be conducted to confirm these assumptions. We report the case of a woman with obesity, which is a risk factor for deep vein thrombosis in the legs and for pulmonary embolism, who experienced fulminant VITT after AZD1222 vaccine administration.
Reference12 articles.
1. Anti-PF4 testing for vaccine- induced immune thrombocytopenia and thrombosis and heparin induced thrombocytopenia: Results from a UK National External Quality Assessment Scheme exercise April 2021;Reilly-Stitt;J Thromb Haemost,2021
2. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis;Pavord;N Engl J Med,2021
3. Risk of Vaccine-Induced Thrombotic Thrombocytopenia (VITT) following the AstraZeneca/ COVISHIELD Adenovirus Vector COVID-19 Vaccines;Chan;Science Briefs of the Ontario COVID-19 Science Advisory Table,2021
4. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia;Cines;N Engl J Med,2021
5. Recommendations on the use of COVID-19 vaccines: Public Health Agency of Canada,2021